PYC Therapeutics

Life-changing science

Investor webinar

October 2025

Disclaimer

The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by PYC Therapeutics and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside PYC's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Q4 investor webinar agenda

- Address the recent changes to the Board and management of PYC
- Provide an update on PYC's drug development pipeline by asset
  - Phelan McDermid Syndrome (PYC-002)
  - Polycystic Kidney Disease (PYC-003)
  - Retinitis Pigmentosa type 11 (VP-001)
  - Autosomal Dominant Optic Atrophy (PYC-001)
- Provide an overview of the Company's commercialisation and capital management plan
- Q&A

PYC has built a pipeline of drug candidates with the potential to become the standard of care in areas of major unmet need

PYC Therapeutics



1. Based on management's latest estimates accurate as at 10 October 2025 and subject to successful realisation of developmental milestones in each program as well as satisfaction of regulatory requirements and subject to all other risks customary to an early-clinical stage biotechnology company developing novel drug candidates
2. See references in Company presentation of 14 March 2024 for source material on prevalence by indication
3. PYC 97% ownership of VP-001 (3% ownership by Lions Eye Institute, Australia) and 100% ownership of all other pipeline programs

PYC's objectives over the coming 24 months

Program	2026/2027 objectives[1]
Polycystic Kidney Disease	• Establish single dose human safety in healthy volunteers and PKD patients • Establish multiple dose human safety in PKD patients • Generate clinical proof-of-concept data (12-month MAD study data) • Progress into an open label extension of the MAD study to evaluate 12 month + data on the confirmatory eGFR endpoint • Initiation of a registrational trial in the US
Phelan-McDermid Syndrome	• Progress into a combined Phase 1/2 first in human study • Establish single dose safety in PMS patients • Generate early human efficacy data
Retinitis Pigmentosa type 11	• Generate safety and efficacy data from >12 months of continuous dosing in RP11 patients including cross-over of the 'fellow' eye • Initiate a registrational trial in the US and EU
Autosomal Dominant Optic Atrophy	• Establish multiple dose human safety in ADOA patients • Generate safety and efficacy data from >12 months of continuous dosing in ADOA patients including cross-over of the 'fellow' eye • Initiation of a registrational study

1. Based on management's latest estimates accurate as at 10 October 2025 and subject to successful realisation of developmental milestones in each program as well as satisfaction of regulatory requirements. Subject to the risks and uncertainties outlined in the Company's ASX disclosures of 17 February 2025

PYC Therapeutics

Life-changing science

Q&A